Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
19, TheFly reported that Cathie Wood's ARK Investment has acquired 755,538 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in a $3,354,588 transaction. This purchase is a testament to the ARK's growing interest in the biotech sector and aligns with its aim to invest in innovative companies. Earlier, on December 17, JPMorgan upgraded Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, while increasing its price target to $11.00 from $10.00. This follows the company's promising results from MEK 1/2 inhibitor, REC-4881, which showcased robust efficacy in FAP patients during the TUPELO trial. The firm believes that the addressable patient population for the treatment is larger than previously anticipated. Looker_Studio/Shutterstock.com JPMorgan sees huge potential for REC-4881 in the United States, forecasting peak sales surpassing $1 billion with a 60% probability of success. Additionally, the investment bank highlighted REC-617, a CDK7 inhibitor that
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 [Seeking Alpha]Seeking Alpha
- Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock, up previously from $10.00.MarketBeat
- Recursion Pharmaceuticals (NASDAQ:RXRX) was given a new $11.00 price target on by analysts at UBS Group AG.MarketBeat
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 144
- 12/17/25 - Form 4
- RXRX's page on the SEC website